Atossa Therapeutics Announces Full Result From KARISMA-Endoxifen Trial

TipRanksDec 11 08:20 ET

Atossa Therapeutics Announces Resuts From Phase 2 KARISMA-Endoxifen Study

TipRanksDec 11 08:20 ET

Atossa Therapeutics Announces Full Results From Phase 2 KARISMA-Endoxifen Study To Be Presented At 2024 San Antonio Breast Cancer Symposium; Demonstrated Statistically Significant Reductions In Mammographic Breast Density

BenzingaDec 11 08:17 ET

Express News | Atossa Therapeutics: 2 Mg Dose Was Associated With Higher Rates of Hot Flashes, Night Sweats and Vaginal Discharge

ReutersDec 11 08:16 ET

Express News | Atossa Therapeutics - 1 Mg Dose Reduced Mbd by 17.3 Percentage Points, 2 Mg Dose by 23.5 Vs Minimal Change in Placebo Group of 0.27

ReutersDec 11 08:15 ET

Express News | Atossa Therapeutics Inc - 1 Mg Dose (Z)-Endoxifen Shows Potential as Preventative Breast Cancer Therapy

ReutersDec 11 08:15 ET